Macrophage lncRNA SIMALR at TNFAIP3 risk locus encodes HLA class II-binding micropeptides in type 1 diabetes

Type 1 diabetes is a condition where the body's own immune system mistakenly attacks and destroys the cells in the pancreas that make insulin. For decades, scientists have known that a person's genetic code holds the clues to why this happens. While some of these clues are found in the famous HLA region, which acts like a major control center for the immune system, researchers have also identified dozens of other genetic spots that increase the risk of the disease. The problem is that most of these spots do not contain instructions for making proteins, the workhorses of our cells. Instead, they sit in what scientists call the "dark genome," a vast area of DNA that was once thought to be silent or useless. The big question has been: what is happening in these dark regions, and how do they trigger an attack on the pancreas?

A new study by independent researcher Reza Anvaripour shines a light on one of these mysterious spots. Located on chromosome 6, this area is known to be a strong risk factor for type 1 diabetes, but until now, no one knew exactly which gene or molecule was responsible for the danger. The researcher focused on a specific genetic variant, a tiny change in the DNA code, that is linked to the disease. By looking at how human cells respond to the chemical signals of inflammation, the study uncovered a hidden player: a long strand of genetic material called SIMALR. This molecule, found in immune cells called macrophages, appears to be a key piece of the puzzle, potentially offering a new explanation for how the immune system is tricked into attacking the body.

The investigation began by taking human pancreatic cells, the very cells that get destroyed in type 1 diabetes, and exposing them to a cocktail of inflammatory chemicals. These chemicals mimic the environment of an active immune attack. The researchers then watched how the cells reacted, specifically looking for changes in the dark genome. They found that when these cells were stressed by inflammation, they woke up a large number of previously silent genetic strands. Among the fifty-four strands that became active, one stood out. It was SIMALR, a long non-coding RNA molecule located just 59,000 letters away from the known risk spot on the chromosome.

What made SIMALR so interesting was its behavior. It appeared in every single one of the nineteen donors tested, turning on strongly whenever the inflammatory chemicals were present. Crucially, this reaction was specific to the type of diabetes being studied. When the researchers looked at cells from people with type 2 diabetes, a different form of the disease, SIMALR remained silent. This suggests that the molecule is not just a general response to stress, but a specific part of the mechanism behind type 1 diabetes. The study also found that SIMALR is regulated by two major switches in the cell, known as NF-kB and STAT3, which are famous for controlling how the immune system responds to threats.

The most surprising discovery came when the researchers looked closer at the SIMALR molecule itself. Although it was classified as "non-coding," meaning it was not supposed to make proteins, the study predicted that it actually hides short instructions for making tiny pieces of protein called micropeptides. The researchers used computer models to see if these tiny pieces could fit into the locks of the immune system, specifically the HLA class II molecules that are known to be involved in type 1 diabetes. The results were striking. The models predicted that several of these micropeptides would bind tightly to the immune locks associated with the disease, particularly a type called DQ8 and another called DRB1*03:01.

Perhaps most importantly, these tiny peptides did not look like any of the known targets of the immune attack. In type 1 diabetes, the immune system usually attacks specific proteins made by the insulin-producing cells, such as insulin itself or GAD65. The researchers compared the SIMALR peptides against a database of over 1,900 known targets and found no matches. This suggests that SIMALR could be presenting a completely new kind of target to the immune system, one that does not come from the beta cells themselves but from the immune cells surrounding them. This would mean the immune system is attacking a different kind of antigen, expanding the known scope of the disease.

To see if this molecule exists in the real world, the researchers checked data from human blood samples. They found that SIMALR is present in monocytes, a type of white blood cell that acts as a macrophage. While the molecule was detectable in the blood, its levels did not clearly separate people with type 1 diabetes from healthy people in the large datasets they examined. However, in a smaller group of people who were in the early stages of developing the disease, the levels of SIMALR appeared higher, hinting that it might be most active during the onset of the condition.

The study also faced a significant hurdle when it tried to find these tiny peptides in actual tissue. The researchers searched a massive database of peptides found in human pancreatic cells, but they did not find any SIMALR pieces. This negative result is not necessarily a failure; it likely means that the peptides are produced in such small amounts or in such a specific type of cell within the pancreas that they are too rare to be caught in a general search. The researchers suggest that to find them, scientists would need to look specifically at the immune cells living inside the pancreas, rather than the whole organ mixed together.

The paper concludes that SIMALR is a strong candidate for being the missing link at this specific genetic risk spot. It is a molecule that turns on only when the immune system is in a state of inflammation, it is found in immune cells, and it produces tiny protein fragments that the immune system is known to react to in type 1 diabetes. While the study is based on computer analysis and existing data rather than new lab experiments, it provides a clear and testable hypothesis. It suggests that the immune system might be attacking a new target, one that lives in the macrophages rather than the insulin cells. This opens a new door for understanding the disease, moving the focus from just the cells being destroyed to the immune cells that are doing the destroying. The next step for science is to take this prediction into the lab and see if these tiny peptides are indeed being shown to the immune system in patients with type 1 diabetes.